more data would be nice but its better than no data at all....most biotechs dont release any clinical trial data this early.....
one other call out on the subject of complete remissions and the number of cycles....it looks like we are tracking higher than the Aza and Venetoklax pivotal on CR/CRis after one cycle. CHMs AVENT trial so far has 66% CR/CRi rate with two out of the 3 patients likely to have undergone one cycle of AZA,Ven and Core NK (out of a total of 4) whereas the AZ and Venetoklax pivotal trial has 43% CR/CRi after first cycle...CHM has a very small sample I know but this is encouraging...
https://www.nejm.org/doi/full/10.1056/NEJMoa2012971
Ann: ADVENT-AML Phase 1B clinical trial update, page-96
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
0.4¢ |
Change
0.000(0.00%) |
Mkt cap ! $8.060M | |||
| Open | High | Low | Value | Volume |
| 0.5¢ | 0.5¢ | 0.4¢ | $15.69K | 3.919M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 26 | 21936206 | 0.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.5¢ | 24685267 | 27 |
View Market Depth
| Last trade - 16.10pm 13/06/2025 (20 minute delay) ? |
| CHM (ASX) Chart |